Allergy Immunotherapy Market Size, Share, Growth, Trends, Company Analysis, Regional Insights and Forecast 2020 - 2027

Allergy Immunotherapy Market Size, Share & Trends Analysis Report - By Region, And Segment Forecasts, 2020 - 2030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Allergy Immunotherapy Market, By Treatment Type

7.1.  Allergy Immunotherapy Market, By Treatment Type, 2020-2030

7.1.1.    Subcutaneous Immunotherapy (SCIT)

7.1.1.1.        Market Revenue and Forecast (2016-2030)

7.1.2.    Sublingual Immunotherapy (SLIT)

7.1.2.1.        Market Revenue and Forecast (2016-2030)

Chapter 8.  Global Allergy Immunotherapy Market, By Allergy Type

8.1.  Allergy Immunotherapy Market, By Allergy Type, 2020-2030

8.1.1.    Allergic Rhinitis

8.1.1.1.        Market Revenue and Forecast (2016-2030)

8.1.2.    Allergic Asthma

8.1.2.1.        Market Revenue and Forecast (2016-2030)

Chapter 9.  Global Allergy Immunotherapy Market, By Distribution Channel

9.1.  Allergy Immunotherapy Market, by Distribution Channel, 2020-2030

9.1.1.    Hospital Pharmacy

9.1.1.1.        Market Revenue and Forecast (2016-2030)

9.1.2.    Retail Pharmacy

9.1.2.1.        Market Revenue and Forecast (2016-2030)

9.1.3.    Online Pharmacy

9.1.3.1.        Market Revenue and Forecast (2016-2030)

Chapter 10.      Global Allergy Immunotherapy Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, By Treatment Type (2016-2030)

10.1.2.  Market Revenue and Forecast, By Allergy Type (2016-2030)

10.1.3.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, By Treatment Type (2016-2030)

10.1.4.2.      Market Revenue and Forecast, By Allergy Type (2016-2030)

10.1.4.3.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, By Treatment Type (2016-2030)

10.1.5.2.      Market Revenue and Forecast, By Allergy Type (2016-2030)

10.1.5.3.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, By Treatment Type (2016-2030)

10.2.2.  Market Revenue and Forecast, By Allergy Type (2016-2030)

10.2.3.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, By Treatment Type (2016-2030)

10.2.4.2.      Market Revenue and Forecast, By Allergy Type (2016-2030)

10.2.4.3.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, By Treatment Type (2016-2030)

10.2.5.2.      Market Revenue and Forecast, By Allergy Type (2016-2030)

10.2.5.3.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, By Treatment Type (2016-2030)

10.2.6.2.      Market Revenue and Forecast, By Allergy Type (2016-2030)

10.2.6.3.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, By Treatment Type (2016-2030)

10.2.7.2.      Market Revenue and Forecast, By Allergy Type (2016-2030)

10.2.7.3.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, By Treatment Type (2016-2030)

10.3.2.  Market Revenue and Forecast, By Allergy Type (2016-2030)

10.3.3.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, By Treatment Type (2016-2030)

10.3.4.2.      Market Revenue and Forecast, By Allergy Type (2016-2030)

10.3.4.3.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, By Treatment Type (2016-2030)

10.3.5.2.      Market Revenue and Forecast, By Allergy Type (2016-2030)

10.3.5.3.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, By Treatment Type (2016-2030)

10.3.6.2.      Market Revenue and Forecast, By Allergy Type (2016-2030)

10.3.6.3.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, By Treatment Type (2016-2030)

10.3.7.2.      Market Revenue and Forecast, By Allergy Type (2016-2030)

10.3.7.3.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, By Treatment Type (2016-2030)

10.4.2.  Market Revenue and Forecast, By Allergy Type (2016-2030)

10.4.3.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, By Treatment Type (2016-2030)

10.4.4.2.      Market Revenue and Forecast, By Allergy Type (2016-2030)

10.4.4.3.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, By Treatment Type (2016-2030)

10.4.5.2.      Market Revenue and Forecast, By Allergy Type (2016-2030)

10.4.5.3.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, By Treatment Type (2016-2030)

10.4.6.2.      Market Revenue and Forecast, By Allergy Type (2016-2030)

10.4.6.3.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, By Treatment Type (2016-2030)

10.4.7.2.      Market Revenue and Forecast, By Allergy Type (2016-2030)

10.4.7.3.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, By Treatment Type (2016-2030)

10.5.2.  Market Revenue and Forecast, By Allergy Type (2016-2030)

10.5.3.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, By Treatment Type (2016-2030)

10.5.4.2.      Market Revenue and Forecast, By Allergy Type (2016-2030)

10.5.4.3.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, By Treatment Type (2016-2030)

10.5.5.2.      Market Revenue and Forecast, By Allergy Type (2016-2030)

10.5.5.3.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

Chapter 11.  Company Profiles

11.1.              ASIT Biotech

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Circassia

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Mylan N.V.

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Adamis Pharmaceuticals Corporation

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Merck KGaA

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Stallergenes Greer plc

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Allergy Therapeutics

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              ALK-Abelló A/S

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              DESENTUM OY

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           HAL Allergy B.V.

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

11.11.           HollisterStier Allergy

11.11.1.               Company Overview

11.11.2.               Product Offerings

11.11.3.               Financial Performance

11.11.4.               Recent Initiatives

11.12.           LETIPharma

11.12.1.               Company Overview

11.12.2.               Product Offerings

11.12.3.               Financial Performance

11.12.4.               Recent Initiatives

11.13.           DBV Technologies SA

11.13.1.               Company Overview

11.13.2.               Product Offerings

11.13.3.               Financial Performance

11.13.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

Glossary of Terms